Excerpt: Adrenocortical carcinoma (ACC) is a rare endocrine neoplasia, characterized by an overall dismal prognosis and its clinical manifestations are the consequence of either steroid excess or tumor mass progression. Surgery is the mainstay of therapy. For patients with locally advanced or metastatic ACC, not amenable to surgery, Mitotane and cytotoxic chemotherapy (with etoposide, doxorubicin and cisplatin - EDP scheme) are the systemic treatments currently in use.
Immunotherapy failure in adrenocortical cancer: where next?
Cosentini, Deborah;Grisanti, Salvatore;LAGANA', MARTA;Fiorentini, Chiara;Sigala, Sandra;Berruti, Alfredo
2018-01-01
Abstract
Excerpt: Adrenocortical carcinoma (ACC) is a rare endocrine neoplasia, characterized by an overall dismal prognosis and its clinical manifestations are the consequence of either steroid excess or tumor mass progression. Surgery is the mainstay of therapy. For patients with locally advanced or metastatic ACC, not amenable to surgery, Mitotane and cytotoxic chemotherapy (with etoposide, doxorubicin and cisplatin - EDP scheme) are the systemic treatments currently in use.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Endocrine Connections] Immunotherapy failure in adrenocortical cancer_ where next_.pdf
accesso aperto
Descrizione: published paper
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
508.58 kB
Formato
Adobe PDF
|
508.58 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
